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Abstract
Introduction: Familial hypocalciuric hypercalcemia is a rare benign autosomal-dominant genetic disease with high
penetrance. In most cases, patients with familial hypocalciuric hypercalcemia experience unspecific physical
discomfort or asymptomatic disease. These patients are typically characterized by mild to moderately increased
blood ionized calcium and a normal to slightly elevated serum parathyroid hormone.
Case presentation: Four female patients with familial hypocalciuric hypercalcemia with inactivating mutations in
the CaSR gene were included in the treatment study. Three patients were related: two were siblings and one was
the daughter of one of these. The ages of the related patients were 51 years, 57 years and 35 years. All three
patients were carriers of the same mutation. The fourth patient, unrelated to the others, was 53 years old, and a
carrier of a novel and previously unknown mutation leading to familial hypocalciuric hypercalcemia. All four
patients were Caucasians of Danish nationality. Biochemically, all patients had elevated blood ionized calcium,
serum parathyroid hormone, serum magnesium and total serum calcium, except one, whose serum parathyroid
hormone was within the normal range prior to treatment. All patients were treated with cinacalcet in a dosage of
30 mg to 60 mg per day.
Conclusion: Three months after the initiation of cinacalcet treatment, all our patients experiencing clinical signs of
hypercalcemia had improved in self -reported well-being and in biochemical parameters. None of our patients
suffered adverse events to cinacalcet treatment. Biochemical markers of calcium homeostasis were improved and
remained stable during the observation period of 12 months (two patients), 24 and 36 months, in both the
symptomatic and the asymptomatic patients.
Introduction
Familial hypocalciuric hypercalcemia (FHH) is a rare,
benign syndrome affecting the regulation of calcium
metabolism. FHH is an autosomal-dominant genetic dis-
ease with high penetrance, caused by an inactivating
mutation in the gene encoding the calcium sensing
receptor, CaSR. The loss-of-function leads to decreased
sensitivity of the CaSR to ionized calcium (Ca
++), shifting
the set-point for Ca
++-regulated parathyroid hormone
(PTH) release to the right [1]. This set-point shift is fol-
lowed by an increased circulating level of PTH and sub-
sequent hypercalcemia. However, blood (B)-Ca
++ is
usually only moderately elevated in FHH patients, as is
the level of serum (S)-PTH. In FHH, urinary calcium
excretion is reduced and the renal tubular reabsorption
of Ca
++ and ionized magnesium (Mg
++) is increased.
Patients with FHH usually present with S-Mg
++ concen-
trations in the upper end of the normal reference interval
or it is only mildly elevated. In most cases, they do not
experience as severe symptoms of hypercalcemia as those
seen in primary hyperparathyroidism: cognitive dysfunc-
tion, kidney stones and skeletal complications. In most
cases, patients with FHH are asymptomatic, or have a
h i s t o r yo fo n l ym i l ds y m p t o m s, described as vertigo,
uneasiness, feeling faint, tartar, muscle soreness or poor
memory [2].
Calcimimetics are allosteric modulators of the CaSR.
They increase the sensitivity and the expression of the
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Cinacalcet induces a transient left-shift of the calcium
set-point by increasing the sensitivity of the receptor to
Ca
++, thereby decreasing the level of S-PTH [3,4]. For
several years, the calcimimetic cinacalcet (Sensipar or
Mimpara) has been used for the treatment of primary
hyperparathyroidism (PHPT), hypercalcemia associated
with parathyroid adenomas [5,6], parathyroid hyperpla-
sia due to kidney disease [7] and parathyroid cancer [8].
It has been shown that, after one year of treatment, the
average pre-dose reduction in S-PTH is 7.6% in PHPT
patients [5]. In a five-year PHPT treatment study, cina-
calcet treatment maintained a reduced S-calcium and
S-PTH in the patients [9]. The effect of cinacalcet on S-
calcium and S-PTH has also been shown to persist for
at least three years of treatment without dose modifica-
tions in patients with secondary hyperparathyroidism
(SHPT) [7]. However, no significant effect has yet been
seen on bone mineral density (BMD) after long-term
treatment of PHPT or SHPT patients with cinacalcet
[5,10].
Cinacalcet is potentially a useful treatment of patients
with intractable hypercalcemia caused by mutations in the
CaSR gene [4,5]. In three patients with FHH with the
amino acid changes F809L [11], R220W [12] and R220Q
[13], and in one patient with neonatal hyperparathyroid-
ism with the mutation R185Q [14], a significant reduction
of hypercalcemia was observed during cinacalcet
treatment.
In the present study, the clinical and biochemical
effects of cinacalcet treatment from 12 months to 36
months are assessed in four female patients with FHH.
Case presentation
Four female patients with FHH were referred to our outpa-
tient clinic at the Research Centre of Ageing and Osteo-
porosis. Three of the patients carry the previously reported
inactivating mutation (R220W)i nt h eCaSR gene [15].
Case 1
Case 1 (I-1) was a 51-year-old Caucasian woman of Dan-
ish nationality. She presented with elevated B-Ca
++ and S-
calcium (total), together with slightly elevated S-PTH. Her
calcium/creatinine clearance ratio was < 0.01 and she was
a carrier of the inactivating (R220W)m u t a t i o ni nt h e
CaSR gene. She experienced muscle cramps and muscle
aches and poor memory. Furthermore, she suffered from
paresthesia in her extremities, uneasiness and osteoporosis
of the spine, with a BMD T-score (mean of lumbar verteb-
rae, L1-L4) of -3.1 prior to cinacalcet treatment.
Case 2
Case 2 (I-2) was a 57-year-old Caucasian woman of
Danish nationality. She presented with elevated B-Ca
++
and S-calcium (total), together with slightly elevated S-
PTH. Her calcium/creatinine clearance ratio was <
0.01. This patient was a carrier of the inactivating
(R220W) mutation in the CaSR gene and was the sister
of patient I-1. She also experienced muscle cramps and
muscle aches and poor memory prior to cinacalcet
treatment.
Case 3
Case 3 (II-1) was a 35-year-old Caucasian woman of
Danish nationality, and the daughter of Case 2 (see the
pedigree in Figure 1). She presented with elevated B-Ca
++
and S-calcium (total), normal values of S-PTH. Her cal-
cium/creatinine clearance ratio was < 0.01. This patient
was a carrier of the inactivating (R220W) mutation in the
CaSR gene. She was asymptomatic with normal BMD
and no cognitive symptoms or other clinical signs of
hypercalcemia.
All three related patients initiated cinacalcet treatment
in a dosage of 30 mg once daily. After one to three months
of treatment, all of them had their dose increased to 30 mg
twice daily. Due to adverse events, such as eye palpitation,
the dose for patient I-1 was reduced to 30 mg once daily.
The eye palpitation disappeared within days.
The biochemical data are presented in Table 1. In all
cases, their B-Ca
++ was found to be significantly lowered
(range of reduction of 11% to 13%, P < 0.01) at first mea-
surement (data not shown). The significant B-Ca
++ lower-
ing persisted after one year (P < 0.01) and, in patient I-2,
after three years (P < 0.01). In all three cases, their S-PTH
levels were significantly decreased after one year of treat-
ment (P < 0.05) and, in case I-2, after three years (P <
0.05) (Table 1). In patient I-1 and I-2, spine and hip BMD
were re-evaluated after one year and three years of treat-
ment. No significant improvement could be detected upon
treatment.
Prior to treatment, patient I-1 and patient I-2 suffered
hypercalcemic symptoms. Both patients reported
improved well-being after only a few months of cinacalcet
treatment. They also no longer reported muscle cramps or
muscle ache. However, the degree of reduced memory was
unchanged. Patient I-1, who suffered paresthesia in her
extremities and uneasiness, reported that her symptoms
had disappeared upon treatment.
Case 4
Case 4 was a 53-year-old Caucasian woman of Danish
nationality. She presented with elevated B-Ca
++ and
S-calcium (total), together with elevated S-PTH. Her cal-
cium/creatinine clearance ratio was < 0.01. Patient was
carrier of a novel heterozygous de novo inactivating
mutation in the CaSR gene leading to FHH. This muta-
tion was a missense mutation caused by a substitution of
amino acid glycine (G) for arginine (R) in the
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been published. Patient 4 suffered clinical symptoms of
tartar, vertigo and constipation. Measurement of her
BMD showed values within normal range.
Patient 4 was initially treated with 30 mg cinacalcet
once daily but the dosage was increased to 30 mg cina-
calcet twice daily from month three.
The biochemical measurements are presented in Table
1. Her B-Ca
++ was significantly lowered by 11% (P < 0.01)
after one month of treatment (data not shown). This
significant B-Ca
++ decrease was maintained at a level even
lower after increased the dosage and her B-Ca
++ was 19%
below baseline (P < 0.01) after the second year (Table 1).
Our patient’s S-PTH was also significantly reduced (P <
0.05) (Table 1). After two years of cinacalcet treatment,
her BMD was unaltered as compared to baseline.
Patient 4 also reported improved well-being after only
a few months of cinacalcet treatment, with the disap-
pearance of symptoms of tartar, vertigo and constipa-
tion. In addition, she reported no adverse events.
WƌŽďĂŶĚ
ƭ
,,
1 2
1
Figure 1 Pedigree of the three related individuals diagnosed with FHH and carrying the R220W mutation. Ι-1 and Ι-2 are symptomatic
and have osteoporosis. ΙΙ-1 is asymptomatic with normal BMD. The amino acid substitution was found in the affected proband in Ι-2 and the
same mutation was revealed in Ι-1 and ΙΙ-1. The filled symbol illustrates the individuals carrying the R220W mutation.
Table 1 Biochemical data of the four patients treated with cinacalcet.
Biochemical data
(normal range)
I-1 I-2 II-1 Case 4
baseline 1 year baseline 1 year 2 years 3 years baseline 2 months 1 year baseline 1 year 2 years
S-Ca(total) (mmol/L)
2.20 to 2.60
3.01 2.74 3.05 2.58 2.71 2.71 3.02 2.51 NA 3.13 2.86 2.87
B-Ca++ (mmol/L)
1.18 to 1.32
1.61 1.43 1.59 1.46 1.44 1.43 1.54 1.36 1.26 1.81 NA 1.47
S-PTH (pmol/L)
1.6 to 6.9
7.3 7.4 7.1 4.4 3.3 1.9 3.5 6.2 2.9 9.0 8.7 8.3
S-phosphate (mmol/L)
0.76 to 1.41
0.70 0.84 0.83 0.93 1.00 NA 0.76 0.98 NA 0.96 0.93 0.79
S-Mg++ (mmol/L)
0.71 to 94
0.96 0.94 1.12 1.00 0.97 0.97 0.97 0.95 NA 0.99 0.94 0.94
S-creatinine (μmol/L)
50 to 90
55 55 59 52 57 NA 49 NA NA 65 63 60
S-alkaline phosphatase (U/L)
35 to 105
124 142 89 105 94 NA 67 NA NA 76 71 70
S-25(OH)-vitamin D (nmol/L)
50 to 178
38 NA NA NA NA NA 85 NA NA 31 NA NA
BMD
T-score spine (L1-L4) -3.6 -3.7 -3.1 -3.0 -3.1 -3.0 -0.1 NA NA -0.4 NA -0.7
T-score hip -3.0 -3.0 -2.2 -2.0 -2.0 -2.0 1.5 NA NA 0.3 NA 0.0
I-1, I-2 and II-1 have an R>Wsubstitution in codon 220 and Case 4 has a G>Rsubstitution in codon 613. Data in bold are outside of the reference range. NA:
not analyzed.
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In the present series of cases, we observed significant
improvement in the calcium homeostasis as evaluated
by measurements of B-Ca
++, S-calcium (total), S-magne-
sium and S-PTH, which is in accordance with other
case reports [11-13]. Furthermore, the observations are
in line with observations from PHPT patients with a
cinacalcet treatment of up to five years duration [5]. In
our case series, after observing for one year in two
patients, two years in one patient and three years in the
fourth patient, cinacalcet treatment was well tolerated
without significant side effects. However, in one case,
eye palpitation was reported at a dosage of 30 mg twice
daily; this symptom disappeared immediately after
dosage reduction. This observation is in accordance
with previous studies published on PHPT [5,6]. In the
three patients experiencing symptoms of hypercalcemia
prior to cinacalcet treatment, we observed self-reported
improvement. For the patient who did not report any
hypercalcemic symptoms prior to treatment, no change
in well-being was reported.
Thus, our biochemical data confirms the observations
of Timmers et al. [11], Festen-Spanjer et al.[ 1 2 ] ,A l o n
and Vandevoorde [13] and Reh et al.[ 1 4 ] ,w h oa l l
reported an effect of cinacalcet on biochemical para-
meters during short-term observation. Our long-term
data show that the biochemical improvement towards
normalization of B-Ca
++ and S-PTH persists for at least
36 months without side effects or the need for a change
in dosage, as observed in one patient case.
In contrast, BMD did not improve in our observed
patients treated with cinacalcet. However, the short obser-
vation time in two patients and only two and three years
of observation in the remaining two patients may account
for this. Although BMD data are sparse, our BMD data are
in accordance with the observations of BMD reported on
cinacalcet treatment in PHPT [5,10].
Our study does have limitations. The data presented
are based on only four FHH cases of an open-label
uncontrolled treatment and changes of hypercalcemic
symptoms are based on self-reported life quality. How-
ever, our four cases are all clinically and biochemically
very well described [15]. They have been followed in
our outpatient clinic for more than 15 years.
Conclusion
In conclusion, in four females with FHH we observed
improvement in their B-Ca
++ and S-PTH upon cinacal-
cet treatment, without significant side effects. The
improvement of the calcium homeostasis persisted for
up to three years without the need for dose escalation.
However, BMD does not seem to be improved during
treatment. In addition, self-reported symptoms of
hypercalcemia in three symptomatic patients improved
or even disappeared whereas one asymptomatic patient
did not report any changes in wellbeing. However, in
order to fully document the usefulness of cinacalcet
treatment in FHH, a randomized controlled trial is
warranted.
Consent
Written informed consent was obtained from the four
patients for publication of this case series and any
accompanying images. A copy of the written consent is
available for review by the Editor-in-Chief of this
journal.
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